In this episode of the “CURE® Talks Cancer” podcast, we spoke with Dr. Naveen Pemmaraju, associate professor of Leukemia at The University of Texas MD Anderson Cancer Center, who recently conducted research on disease awareness in patients with myeloproliferative neoplasms (MPNs).
Many patients with MPNs reported going to the internet to seek out information about their disease; however, many still did not know about some of the common markers of their disease. While the internet can be a great source of information, there is plenty of misinformation available, too, so it is always important that patients take what they find online and talk to their providers about it.
Read more: https://www.curetoday.com/view/how-to-find-reliable-cancer-information-online
Social Media and Rare Cancers: Stay Informed, But Tread With Caution
Social media and the internet as a whole can offer a wealth of information and connections for patients with cancer, especially those with rarer diseases. However, patients should always bring the online advice to their health care team, says Dr. Naveen Pemmaraju.
In this episode of the “CURE® Talks Cancer” podcast, we spoke with Dr. Naveen Pemmaraju, associate professor of Leukemia at The University of Texas MD Anderson Cancer Center, who recently conducted research on disease awareness in patients with myeloproliferative neoplasms (MPNs).
Many patients with MPNs reported going to the internet to seek out information about their disease; however, many still did not know about some of the common markers of their disease. While the internet can be a great source of information, there is plenty of misinformation available, too, so it is always important that patients take what they find online and talk to their providers about it.
Read more: https://www.curetoday.com/view/how-to-find-reliable-cancer-information-online
Patients With Lower-Risk Myelofibrosis May Respond to Jakafi
Although Jakafi has been approved for patients with higher-risk myelofibrosis, those with lower-risk disease may also benefit from this treatment.
Read More
Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Listen
A True Partner in Cancer Healing
Keri is also a true partner in the management and care of the whole patient.
Read More
Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Listen
FDA Approves Niktimvo for Chronic GVHD
Niktimvo was approved for adults and children with chronic, pretreated graft-versus-host disease.
Read More
FDA Accepts Supplemental New Drug Application for Cabometyx in Pancreatic NETs
The FDA will review an application for Cabometyx as a potential treatment for pancreatic neuroendocrine tumors after findings from a phase 3 trial.
Read More
Patients With Lower-Risk Myelofibrosis May Respond to Jakafi
Although Jakafi has been approved for patients with higher-risk myelofibrosis, those with lower-risk disease may also benefit from this treatment.
Read More
Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Listen
A True Partner in Cancer Healing
Keri is also a true partner in the management and care of the whole patient.
Read More
Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Listen
FDA Approves Niktimvo for Chronic GVHD
Niktimvo was approved for adults and children with chronic, pretreated graft-versus-host disease.
Read More
FDA Accepts Supplemental New Drug Application for Cabometyx in Pancreatic NETs
The FDA will review an application for Cabometyx as a potential treatment for pancreatic neuroendocrine tumors after findings from a phase 3 trial.
Read More